Press reports on our research
Psychedelic Medicine Podcast 15/7/2023
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
The FACE 20/7/2023: 'The Dark Side of the Psychedelic Renaissance'
Lynn-Marie Morski interviewed Jules about the Challenging Psychedelic Experiences Project
The FACE 20/7/2023: 'The Dark Side of the Psychedelic Renaissance'
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
The FACE 20/7/2023: 'The Dark Side of the Psychedelic Renaissance'
Simon Doherty interviewed Jules Evans for this feature on psychedelic harms and risks
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
Floris Wolswijk interviewed Anna Lutkajtis and myself on our study of integration challenges after a psychedelic retreat.
Daily Mail 09/1/2023: 'How safe is psychedelic therapy?'
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
Lucid News 15/2/2023: 'Exploring the Challenges of Psychedelic integration'
Psychedelic therapy is becoming increasingly popular, and has been tried by Prince Harry. But we need to learn more about risks and how to manage them, writes John Naish
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
.png/:/cr=t:28.68%25,l:0%25,w:100%25,h:63.09%25/rs=w:388,h:194,cg:true)
An interview with Jules Evans for UC Berkeley's Microdose newsletter
Vice 3/3/2022: 'It's time to start studying the downsides of psychedelics
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
Microdose 3/1/2023: 'Five questions on the challenging psychedelic experiences project'
.png/:/cr=t:0%25,l:0.3%25,w:99.4%25,h:100%25/rs=w:388,h:194,cg:true)
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong, writes Shayla Love
Politico 28/09/2022: 'Navigating the highs and lows of psychedelics'
Medium 21/1/2021: 'Protecting people from the side effects of psychedelic therapy'
Wired 3/11/2022: 'The harms of psychedelics need to be put into context'
.png/:/cr=t:0%25,l:0.65%25,w:98.69%25,h:100%25/rs=w:388,h:194,cg:true)
Regulators face new challenges over whether - and how - to allow people to access mind-altering drugs to treat mental health conditions, writes Helen Collis
Wired 3/11/2022: 'The harms of psychedelics need to be put into context'
Medium 21/1/2021: 'Protecting people from the side effects of psychedelic therapy'
Wired 3/11/2022: 'The harms of psychedelics need to be put into context'
.png/:/cr=t:0%25,l:2.06%25,w:95.87%25,h:100%25/rs=w:388,h:194,cg:true)
As psychedelic therapy trials get bigger and the drugs become more accessible, researchers need to start talking about their potential adverse effects., writes Grace Browne
Medium 21/1/2021: 'Protecting people from the side effects of psychedelic therapy'
Medium 21/1/2021: 'Protecting people from the side effects of psychedelic therapy'
Medium 21/1/2021: 'Protecting people from the side effects of psychedelic therapy'
.png/:/cr=t:19%25,l:0%25,w:100%25,h:62%25/rs=w:388,h:194,cg:true)
Psychedelic companies and investors should invest to learn about and protect people from the risks of psychedelic therapy writes Jules Evans